Caricamento...
Agents to treat BRAF-mutant lung cancer
BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC) patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF mutations are non-V600E. The biologic behavior of BRAF-mutated lung tumors tends to be more aggressive and resistant to chemotherapy...
Salvato in:
| Pubblicato in: | Drugs Context |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioExcel Publishing Ltd
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6419923/ https://ncbi.nlm.nih.gov/pubmed/30899313 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212566 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|